The Quality Lowdown: What Happens When The US FDA Must Choose Between Risks
Executive Summary
Tuberculosis or cancer, sterility assurance or shortages, the choices come at you fast; Takeda, Wintac, Banco Vida updates.
You may also be interested in...
How US FDA Wants Pharmaceutical Production Volumes Reported For Drug Shortage Prevention
Monthly data are expected in annual reports on listed drugs and active ingredients from every registered site, starting in February.
How US FDA Wants Pharmaceutical Production Volumes Reported For Drug Shortage Prevention
Monthly data are expected in annual reports on listed drugs and active ingredients from every registered site, starting in February.
US FDA’s Machine Learning Analysis Suggests Where To Look For Manufacturing Site Quality Problems
XGBoost model sees site complexity contributes to quality risk, but misses device-related issues, says third FDA pharmaceutical quality report.